Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Oncology Companion Diagnostic Market Size & Share 2026-2035
Report ID: GMI13317
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Oncology Companion Diagnostic Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Oncology Companion Diagnostic Market Size
The oncology companion diagnostic market was valued at USD 5.53 billion in 2025, is projected to reach USD 6.06 billion in 2026, and is expected to grow at a CAGR of 8.7% (2026–2035), reaching USD 12.81 billion by 2035.
Oncology Companion Diagnostic Market Key Takeaways
Market Leader: F. Hoffmann-La Roche Ltd led with over 18.1% market share in 2025.
Leading Players: Top 5 players in this market include F. Hoffmann-La Roche Ltd, Agilent Technologies, QIAGEN N.V., Leica Biosystems, Guardant Health, which collectively held a market share of 37.2% in 2025.
The oncology companion diagnostic market is moving from a predominantly single-analyte, tissue-based testing model toward a broader precision-oncology infrastructure that combines validated assays, multi-gene sequencing, digital pathology, bioinformatics, and specialist laboratory services. Growth depends on the clinical need to match molecularly defined patients with paired therapies, while expanding test menus increase the commercial importance of recurring reagents, interpretation software, and centralized testing capacity.
GMI Analyst View
Based on our assessment of documented market performance, we find that the global oncology companion diagnostic market recorded a 7.1% CAGR (2022–2025). That performance indicates that CDx demand had already established a durable clinical and commercial base before the wider rollout of complex genomic panels, creating a stronger foundation for forecast-period expansion than a purely pipeline-led growth narrative would suggest.
Oncology Companion Diagnostic Market Trends, Growth Drivers & GMI Forecast Outlook
Cancer incidence, drug-diagnostic co-development, and the operationalization of complex biomarker interpretation are enlarging the testing opportunity. Realized revenue will depend on whether laboratories can convert clinical demand into reimbursed, standardized testing pathways without delays from authorization sequencing or compliance burdens.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Cancer incidence creates the addressable clinical pool, but the revenue mechanism is more specific: targeted treatment pathways require confirmation of a relevant alteration, receptor, or expression pattern before therapy selection. That requirement makes diagnostic utilization integral to oncology decision-making rather than an optional ancillary procedure. It also supports recurring demand for sample preparation, assay reagents, reporting, and referral testing as biomarker testing becomes embedded earlier in treatment pathways.
Co-development converts pharmaceutical innovation into a defined testing obligation. FoundationOne CDx received four additional companion diagnostic claims during 2024, illustrating how label expansion can deepen utilization of an established platform without requiring a wholly new workflow at each site [2]. The commercial benefit is strongest where laboratories, payers, and prescribers align around a single validated test pathway at launch.
AI-supported reporting is becoming important because the interpretation burden rises faster than the number of physical assays when panels cover multiple biomarkers and indications. Integrated variant review, digital-image analysis, and structured reporting can make advanced CDx workflows more practical for laboratories that lack extensive specialist informatics teams. This shifts value toward platforms that combine assay performance with usable clinical interpretation and compatible laboratory workflows.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Reimbursement gaps are particularly damaging for complex genomic testing because the laboratory must absorb costs before test volume can establish scale economies. When drug coverage and diagnostic coverage proceed through separate assessment routes, a therapeutically eligible patient may still encounter a constrained testing pathway. Laboratories can respond by narrowing menus, using referral networks selectively, or delaying investment in broader panel capability.
Authorization timing produces a different form of friction. If a therapy reaches clinical practice before its paired commercial diagnostic is fully available, laboratories may rely on internally validated or alternative assays. That preserves access to treatment but delays the commercial ramp of the designated product and can complicate standardization across specimen types, analytical thresholds, and reporting formats.
CE-IVDR implementation raises the threshold for sustained participation in European CDx markets. The need for performance evidence, notified-body review, and post-market systems favors developers with established regulatory operations and can make niche indications less attractive for smaller suppliers. The resulting pressure is likely to strengthen the strategic value of scale, portfolio breadth, and established quality infrastructure.
GMI Analyst View
We view the principal forecast tension as one of conversion rather than clinical relevance. Precision oncology is creating clear testing need, but the commercial outcome depends on reimbursement alignment, coordinated drug-diagnostic launches, and laboratories' ability to operationalize higher-complexity workflows. Markets that solve those execution issues should capture demand earlier and more consistently than those where testing access remains fragmented.
Oncology Companion Diagnostic Market Segment Analysis
By Offering
The oncology companion diagnostic market's consumables segment generated USD 2.46 billion in 2025 and is projected to account for 45.0% of market revenue by 2035. Reagent kits, assay components, specimen-preparation materials, and quality-control inputs are consumed with each completed test, making this category closely tied to clinical testing volume. Its position is reinforced as approved indications increase and laboratories process more samples across routine and complex workflows.
The instrument segment is projected to reach USD 2.81 billion by 2035, while representing 25.0% of market revenue in 2025. Sequencers, PCR systems, staining platforms, and digital-pathology hardware remain essential entry points for in-house testing. Demand is shaped by replacement cycles and the migration toward platforms able to support multiplexed assays, but capital purchasing discipline means adoption depends on utilization expectations and laboratory throughput.
Software represented 11.5% of market revenue in 2025 and is expected to expand at a 10.9% CAGR (2026–2035). The segment benefits from the growing interpretive burden associated with multi-gene panels, image analysis, and standardized clinical reporting. Its strategic relevance extends beyond data processing: software increasingly determines whether sophisticated molecular results can be translated into usable, auditable treatment-selection outputs at scale.
Services are projected to generate USD 2.43 billion by 2035 and accounted for 19.0% of market revenue in 2025. Centralized testing providers can distribute the capital, validation, and specialist labor requirements of sequencing and liquid-biopsy workflows over larger specimen volumes. This supports referral-based testing models for hospitals that retain routine pathology activities internally but outsource technically demanding assays.
By Technology
Immunohistochemistry generated USD 1.99 billion in 2025 and is projected to hold 32.0% of technology revenue by 2035. Its installed base, familiar pathology workflow, and role in protein-biomarker assessment preserve its importance across established oncology treatment pathways. IHC remains particularly resilient where tissue morphology and rapid integration into pathology practice are clinically important.
PCR platforms are projected to reach USD 2.81 billion by 2035 and represented 25.0% of technology revenue in 2025. Their durable role reflects short turnaround times, comparatively accessible infrastructure, and suitability for well-defined mutations. PCR remains commercially relevant in settings where high-volume testing and focused biomarker questions do not justify broader sequencing workflows.
Next-generation sequencing represented 22.0% of technology revenue in 2025 and is projected to grow at a 12.2% CAGR (2026–2035). A single panel can support several treatment decisions, improving its clinical proposition as actionable alterations accumulate within an indication. FDA-authorized NGS platforms, including TruSight Oncology Comprehensive CDx, received new companion diagnostic indications during 2024 [2], reinforcing the route by which panel utility expands through label development.
In situ hybridization and FISH are projected to generate USD 1.28 billion by 2035 and accounted for 11.0% of technology revenue in 2025. These methods retain a defined role where copy-number changes and chromosomal rearrangements require an established visualization-based approach. Their continued use reflects regulatory and clinical specificity rather than broad platform substitution.
Other technologies generated USD 332 million in 2025 and are projected to hold 6.0% of technology revenue by 2035. Proteomics-based methods, targeted mass spectrometry, and emerging approaches remain concentrated in niche or developing applications. Their opportunity depends on clinical validation, reproducible workflow integration, and whether they can establish a differentiated role alongside entrenched tissue and genomic testing modalities.
By Disease Type
Breast cancer companion diagnostics generated USD 1.43 billion in 2025 and are projected to account for 24.0% of disease-type revenue by 2035. HER2, hormone-receptor, and emerging resistance-marker testing create a broad, established base across pathology and molecular workflows. Future expansion is likely to be driven more by refinement of treatment selection and progression monitoring than by first-time adoption of longstanding core tests.
Non-small cell lung cancer is projected to generate USD 3.20 billion by 2035 and represented 23.0% of disease-type revenue in 2025. The indication's extensive biomarker landscape makes it a major demand center for sequential and panel-based testing. An estimated 2.64 million lung cancer diagnoses worldwide in 2024 underscore the scale of the underlying testing opportunity [1], while new actionable targets favor comprehensive profiling earlier in the treatment pathway.
Colorectal cancer represented 12.0% of disease-type revenue in 2025 and is projected to reach USD 1.40 billion by 2035. RAS, BRAF, mismatch-repair, and microsatellite-instability testing anchor the current workflow. The segment's development depends on how liquid-biopsy methods and additional molecular classifications are incorporated into treatment selection without displacing established testing requirements.
Leukemia and lymphoma are projected to generate USD 1.28 billion by 2035 and accounted for 10.0% of disease-type revenue in 2025. The testing environment spans mutation profiling, treatment-selection markers, and evolving residual-disease applications. This diversity gives specialist laboratories an advantage where assay sensitivity, longitudinal monitoring, and rigorous clinical interpretation are central to the workflow.
Melanoma generated USD 387 million in 2025 and is projected to account for 6.0% of disease-type revenue by 2035. BRAF-focused testing remains a core source of demand, supported by established therapeutic pathways. Incremental growth will depend on whether additional immunotherapy-related biomarkers achieve sufficiently clear clinical utility and standardized deployment.
Prostate cancer is projected to generate USD 769 million by 2035 and is expected to expand at a 10.7% CAGR (2026–2035). The segment is benefiting from the growing relevance of DNA-damage-response biomarkers in advanced disease. As targeted treatment strategies broaden, the commercial opportunity will favor tests that can deliver reliable molecular results within the timing constraints of late-stage oncology care.
Other disease types accounted for 17.0% of disease-type revenue in 2025 and are projected to represent 18.0% by 2035. This category benefits from the accumulation of biomarker-led therapy opportunities across rarer cancers and tumor-agnostic pathways. Its growth is less dependent on a single high-volume indication and more on the ability of existing diagnostic infrastructure to absorb additional validated uses.
By End Use
Hospitals generated USD 2.26 billion in 2025 and are projected to hold 38.0% of end-use revenue by 2035. They remain central to tissue handling, rapid pathology decisions, and established IHC and PCR workflows. Their relative position is moderated by the tendency to refer high-complexity genomic work to specialist laboratories when in-house scale does not support the required equipment and expertise.
Diagnostic laboratories are projected to generate USD 4.99 billion by 2035 and represented 37.0% of end-use revenue in 2025. Their model is well suited to high-throughput sequencing, liquid biopsy, and centralized bioinformatics because fixed compliance and capital costs can be spread over a broad referral base. This channel is positioned to capture much of the incremental complexity associated with comprehensive genomic profiling.
Academic and research institutions represented 16.0% of end-use revenue in 2025 and are expected to grow at a 9.4% CAGR (2026–2035). These settings remain important for assay validation, translational research, and clinical studies supporting future CDx labels. Their influence on market development exceeds their direct revenue role because they help establish the clinical evidence and operational protocols that later diffuse into routine care.
Other end-use settings generated USD 332 million in 2025 and are projected to account for 6.0% of end-use revenue by 2035. This group includes development laboratories, contract research organizations, and specialized testing facilities. Demand is linked to pharmaceutical development activity and the need for controlled testing capability during pre-approval validation and commercialization preparation.
GMI Analyst View
We see segment value migrating toward capabilities that make complex testing operationally scalable. Consumables retain the closest link to test volume, while NGS and software gain importance as treatment selection relies on broader biomarker coverage and more demanding interpretation. The strongest channel shift is toward specialist laboratories for complex work, even as hospitals retain an essential role in routine pathology and specimen stewardship.
Oncology Companion Diagnostic Market Regional Analysis
North America Oncology Companion Diagnostic Market Analysis
The oncology companion diagnostic market in North America accounted for 44.0% of global revenue in 2025 and is projected to generate USD 5.01 billion by 2035. The region combines established regulatory pathways, broad pharmaceutical co-development activity, and advanced laboratory adoption. Its commercial advantage rests on the ability to connect therapy launch, biomarker testing, and reimbursement more consistently than many other markets.
U.S.
The U.S. generated USD 2.19 billion in 2025 and represented 90.0% of North American revenue that year. The market's depth reflects concentration of CDx development, payer coverage for validated tests, and early adoption of genomic and liquid-biopsy workflows. It remains the principal environment in which new commercial testing models are tested at scale.
Canada
Canada is projected to generate USD 505 million by 2035 and accounted for 10.0% of North American revenue in 2025. Its clinical practice is closely connected to international CDx developments, but provincial reimbursement structures can create uneven access. Centralized testing capacity and payer decisions will determine how quickly advanced panels move beyond selected specialist settings.
Europe Oncology Companion Diagnostic Market Analysis
Europe generated USD 1.27 billion in 2025 and is expected to expand at an 8.0% CAGR (2026–2035). Strong academic oncology networks and precision-medicine initiatives support demand, but national coverage systems and health technology assessment processes can delay commercial uptake. The region's opportunity is substantial where regulatory compliance and reimbursement pathways are aligned.
Germany
Germany is projected to generate USD 612 million by 2035 and represented 23.3% of European revenue in 2025. Its molecular-pathology base and university-hospital networks support adoption of established and complex CDx workflows. The absence of industry-funded testing bridges makes sustainable payer reimbursement particularly important to laboratory menu expansion.
UK
The UK generated USD 255 million in 2025 and is expected to grow at an 8.5% CAGR (2026–2035). Centralized genomic-service infrastructure provides a route for broader panel deployment, particularly in specialist oncology pathways. However, implementation timing remains shaped by public-pathology budgets and the translation of guidelines into funded service capacity.
France
France is projected to generate USD 495 million by 2035 and accounted for 18.9% of European revenue in 2025. Structured molecular tumor-board networks support biomarker-guided treatment decisions. Access to newer assays depends on coverage and laboratory funding decisions, creating a commercial environment where clinical demand may precede routine test availability.
Italy
Italy generated USD 198 million in 2025 and is projected to account for 15.5% of European revenue by 2035. Its market is shaped by meaningful regional variation in laboratory capability and budget allocation. Referral networks and targeted funding mechanisms can support access, but they do not fully eliminate disparities between better-resourced and constrained care settings.
Spain
Spain is projected to generate USD 380 million by 2035 and represented 13.4% of European revenue in 2025. Comprehensive cancer centers and molecular tumor-board activity provide a foundation for CDx uptake. The key commercial question is whether differences across autonomous communities narrow sufficiently to support more consistent testing availability.
Netherlands
The Netherlands represented 8.9% of European revenue in 2025 and is expected to grow at an 8.6% CAGR (2026–2035). A centralized academic-hospital network and comparatively integrated diagnostic pathways support adoption. Its role in international validation studies can also help establish reference-laboratory capability for sophisticated NGS-based testing.
Asia Pacific Oncology Companion Diagnostic Market Analysis
Asia Pacific is projected to generate USD 4.08 billion by 2035 and is expected to grow at an 11.0% CAGR (2026–2035). Demand reflects expanding cancer care infrastructure, domestic platform development, and wider use of targeted therapies across major markets. The region is not homogeneous: commercial progress will be determined by distinct regulatory systems, reimbursement models, and laboratory investment cycles.
China
China generated USD 602 million in 2025 and is expected to expand at a 12.6% CAGR (2026–2035). Domestic assay and sequencing development is broadening the competitive field alongside multinational offerings. Continued progress depends on the ability of regulatory authorization, hospital adoption, and affordability to advance together across a large and diverse care system.
Japan
Japan is projected to generate USD 820 million by 2035 and represented 26.4% of Asia Pacific revenue in 2025. Its structured regulatory environment and universal health-insurance framework support more formalized uptake of approved testing. The market is positioned for disciplined adoption of complex diagnostics where clinical value and reimbursement are clearly established.
India
India accounted for 13.1% of Asia Pacific revenue in 2025 and is projected to grow at a 13.0% CAGR (2026–2035). Expansion is moving from metropolitan hospital programs toward a wider reference-laboratory network. The pace will depend on whether infrastructure investment and access to targeted therapies can extend beyond concentrated urban oncology centers.
South Korea
South Korea is projected to generate USD 451 million by 2035 and represented 12.1% of Asia Pacific revenue in 2025. Its established molecular-diagnostics sector and domestic biopharmaceutical ecosystem support advanced testing adoption. The market is well placed to translate precision-medicine initiatives into routine CDx use where reimbursement and institutional workflows remain supportive.
Australia
Australia generated USD 94 million in 2025 and is projected to account for 5.0% of Asia Pacific revenue by 2035. High clinical-quality standards and established oncology protocols support use of approved tests, while the country's smaller patient base constrains absolute scale. Its significance lies in the quality and structure of adoption rather than regional volume leadership.
Latin America Oncology Companion Diagnostic Market Analysis
Latin America represented 4.0% of global revenue in 2025 and is projected to generate USD 523 million by 2035. Market development is concentrated in major metropolitan private-care networks and specialist laboratories. Broader expansion requires improved reimbursement for advanced molecular diagnostics and more consistent regulatory and distribution infrastructure.
Brazil
Brazil generated USD 122 million in 2025 and is projected to account for 55.3% of Latin American revenue by 2035. Its private insurance sector and molecular-reference-laboratory base give it a leading regional position. Continued growth will depend on whether access extends more effectively into public oncology care and beyond the largest urban centers.
Mexico
Mexico is projected to generate USD 168 million by 2035 and represented 32.1% of Latin American revenue in 2025. Private hospital networks are the principal route for advanced testing uptake. Wider public-sector incorporation of biomarker testing would materially improve the addressable demand base for validated CDx products.
Argentina
Argentina accounted for 12.7% of Latin American revenue in 2025 and is expected to grow at a 9.0% CAGR (2026–2035). Academic oncology expertise supports availability of molecular testing, but macroeconomic volatility and fragmented funding limit predictability. Suppliers must manage distribution, pricing, and reimbursement constraints alongside clinical demand.
Middle East & Africa Oncology Companion Diagnostic Market Analysis
The Middle East & Africa region is projected to account for 3.4% of global revenue by 2035 and is expected to grow at a 10.0% CAGR (2026–2035). Demand is concentrated in Gulf healthcare-investment hubs and South Africa's private oncology sector. Expansion remains closely tied to specialist laboratory capacity, oncology-service modernization, and public funding priorities.
Saudi Arabia
Saudi Arabia generated USD 66 million in 2025 and is projected to account for 42.5% of Middle East & Africa revenue by 2035. Investments in oncology modernization and accredited pathology infrastructure create a foundation for greater CDx deployment. Uptake will be influenced by registration of paired therapies and the operational integration of molecular testing across national cancer-care networks.
UAE
The UAE is projected to generate USD 157 million by 2035 and represented 34.9% of Middle East & Africa revenue in 2025. Advanced private hospitals and the country's role as a regional healthcare hub support demand for validated diagnostic technologies. Its distribution and specialist-laboratory networks also make it an important commercial entry point for broader regional expansion.
South Africa
South Africa represented 25.3% of Middle East & Africa revenue in 2025 and is projected to generate USD 91 million by 2035. Private-sector oncology programs provide the principal base for CDx use, while public-sector capacity remains constrained. The market's longer-term potential depends on whether laboratory infrastructure and funding can expand beyond a relatively concentrated private-care environment.
GMI Analyst View
We assess Asia Pacific as the key source of incremental market momentum, but its expansion will follow several national pathways rather than a single regional model. North America remains the reference market for commercialization and clinical adoption, whereas Europe's opportunity is tempered by reimbursement fragmentation. In emerging regions, laboratory capacity and payment architecture will determine how much clinical demand becomes sustained test revenue.
Oncology Companion Diagnostic Market Share & Competitive Landscape
The oncology companion diagnostics market is characterized by a fragmented competitive structure, with F. Hoffmann-La Roche Ltd (including Foundation Medicine), Agilent Technologies/DAKO, QIAGEN N.V., Leica Biosystems (Danaher), and Guardant Health collectively accounting for approximately 37.2% of global market revenue in 2025. Market competition is driven by expertise across biomarker technologies, regulatory and co-development capabilities, pharmaceutical partnerships, laboratory workflow integration, and installed testing platforms. The presence of multiple diagnostic modalities, including immunohistochemistry (IHC), polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid biopsy, supports a diverse supplier landscape where competitive advantages are often linked to technology specialization and companion diagnostic development expertise.
Other notable competitors include Illumina, Thermo Fisher Scientific, NeoGenomics, Myriad Genetics, Bio-Techne, Exact Sciences, and Natera, which compete through sequencing technologies, molecular testing platforms, laboratory-developed tests, and biomarker discovery capabilities. As precision oncology continues to expand, competition is increasingly focused on biomarker coverage, pharmaceutical partnerships, clinical utility, regulatory approvals, and the ability to provide integrated testing solutions across the patient care pathway rather than on diagnostic technology alone.
Recent Industry Developments
In September 2025, Myriad Genetics and SOPHiA GENETICS global liquid-biopsy CDx collaboration : The companies announced a worldwide collaboration to develop and commercialize a liquid-biopsy companion diagnostic offering. The arrangement combines Myriad's U.S. laboratory and regulatory capabilities with SOPHiA GENETICS' international network and is intended to advance an MSK-ACCESS-based circulating tumor DNA test as a CDx application [7].
In May 30, 2025, QIAGEN and Foresight Diagnostics worldwide lymphoma CDx partnership: The partners announced plans to develop and commercialize a kit-based version of Foresight's CLARITY circulating tumor DNA minimal residual disease assay for lymphoma and other hematological malignancies. The initiative pairs high-sensitivity detection technology with QIAGEN's global development and commercialization infrastructure [6].
In December 18, 2024, Guardant Health and Boehringer Ingelheim HER2-mutant NSCLC collaboration : The companies announced a collaboration to pursue regulatory approval of Guardant360 CDx as a companion diagnostic for zongertinib in HER2-mutant NSCLC. The initiative highlights continued pharmaceutical interest in blood-based profiling where repeat tissue biopsy may be clinically difficult [5].
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →